SCHEMBL790240

SCHEMBL790240

C[Si](C)(C)C#CCCCO

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL789558 0.92 ALDH1A1 (0.33) ALDH1A1
SCHEMBL23015187 0.90 LMNA (0.36) ALDH1A1
SCHEMBL1535208 0.90 LMNA (0.36) ALDH1A1
SCHEMBL23014944 0.90 LMNA (0.36) ALDH1A1
SCHEMBL23015167 0.90 LMNA (0.36) ALDH1A1
SCHEMBL103659 0.83
SCHEMBL1353429 0.83 SELP (0.32)
SCHEMBL20639270 0.83
SCHEMBL16420274 0.83 RAB9A (0.33)
SCHEMBL31725737 0.80 RAB9A (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110206834-A1 CURABLE COMPOSITION FOR TRANSFER MATERIALS, AND PATTERN FORMING PROCESS SHOWA DENKO K.K. (JP) 2011-08-25 US claimed
EP-2345676-A1 CURABLE COMPOSITION FOR TRANSFER MATERIAL AND PATTERN FORMATION METHOD SHOWA DENKO K.K. (JP) 2011-07-20 EP claimed
US-20240376094-A2 SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE LES LABORATOIRES SERVIER (FR) 2024-11-14 US disclosed
US-20240182464-A1 SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE Les Laboratoirens Serviece (FR) 2024-06-06 US disclosed
CN-114450283-B 3, 6-Diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents 法国施维雅药厂 2024-05-07 CN disclosed
EP-3782996-B1 NRF2 REGULATORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-04-10 EP disclosed
EP-3555078-B1 BISARYL HETEROCYCLES AS NRF2 ACTIVATORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-03-27 EP disclosed
EP-4288434-A1 SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE Les Laboratoires Servier (FR) 2023-12-13 EP disclosed
US-11814462-B2 Functionalized cyclic polymers and methods of preparing same UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-11-14 US disclosed
WO-2023140369-A1 PHOSPHORIC ACID DERIVATIVES Prism BioLab Co., Ltd. (JP) 2023-07-27 WO disclosed
CN-110546146-B Heteroaryl carboxamide derivatives as plasma kallikrein inhibitors 勃林格殷格翰国际有限公司 2023-02-21 CN disclosed
US-20110245528-A1 THERAPEUTIC COMPOUNDS SCHWARTZ C ERIC 2011-10-06 US disclosed
US-20110206834-A1 CURABLE COMPOSITION FOR TRANSFER MATERIALS, AND PATTERN FORMING PROCESS SHOWA DENKO K.K. (JP) 2011-08-25 US disclosed
EP-2345676-A1 CURABLE COMPOSITION FOR TRANSFER MATERIAL AND PATTERN FORMATION METHOD SHOWA DENKO K.K. (JP) 2011-07-20 EP disclosed
WO-2010039531-A1 THERAPEUTIC COMPOUNDS RESOLVYX PHARMACEUTICALS, INC. (US) 2010-04-08 WO disclosed
US-20090191479-A1 RESIN COMPOSITION FOR LASER ENGRAVING, RELIEF PRINTING PLATE PRECURSOR FOR LASER ENGRAVING, RELIEF PRINTING PLATE AND METHOD OF PRODUCING THE SAME FUJIFILM CORPORATION (JP) 2009-07-30 US disclosed
US-7229987-B2 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes ELI LILLY AND COMPANY (US) 2007-06-12 US disclosed
US-20050272718-A1 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes AMMENN ET AL, JOCHEN 2005-12-08 US disclosed
EP-1505968-A1 MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES ELI LILLY AND COMPANY (US) 2005-02-16 EP disclosed
WO-2003097047-A1 MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES ELI LILLY AND COMPANY (US) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245528-A1 THERAPEUTIC COMPOUNDS ALOX5, ALOX15B, ALOX12 ALDH1A1 1616/4885
US-20240182464-A1 SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE CRBN, XIAP, BCL2L11 ALDH1A1 3085/4885
US-20240376094-A2 SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE CRBN, XIAP, BCL2L11 ALDH1A1 3085/4885
US-20050272718-A1 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes MC1R, MC4R, MC5R ALDH1A1 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.